Prospective study of barrier contraception for the prevention of sexually transmitted diseases: Study design and general characteristics of the study group

Sexually Transmitted Diseases

Volumn 26, Issue 3, 1999, Pages 127-136

  Macaluso, Maurizio ^a   Artz, Lynn ^a   Kelaghan, Joseph ^b   Austin, Harland ^c   Fleenor, Michael ^d   Hook III, Edward W ^d,e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c EMORY UNIVERSITY   (United States)

^d Jefferson County Department of Health   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SPERMICIDAL AGENT;

ADULT; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONDOM; CONTRACEPTION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GONORRHEA; HEALTH EDUCATION; HERPES SIMPLEX VIRUS 2; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; NEGRO; NEISSERIA GONORRHOEAE; PATIENT COUNSELING; PROSPECTIVE STUDY; SEXUALLY TRANSMITTED DISEASE; TREPONEMA PALLIDUM; TRICHOMONAS VAGINALIS;

EID: 0032993347     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-199903000-00002     Document Type: Article

References (50)

1. Koop CE. Understanding AIDS - a message from the Surgeon General. HHS Publication No. (CDC) HHS-88-8404, May 1988.
2. North BB. Vaginal contraceptives: effective protection from sexually transmitted diseases for women? J Reprod Med 1988; 33:307-311.
3. Horsburgh CR, Douglas JM, LaForce FM. Preventive strategies in sexually transmitted diseases for the primary care physician. JAMA 1987; 258:815-821.
4. Condoms for prevention of sexually transmitted diseases. MMWR 1988; 37:133-137.
5. Goldsmith MF. Sex in the age of AIDS calls for common sense and "condom sense." JAMA 1987; 257:2261-2263.
6. Mosher WD, Pratt WF. Contraceptive use in the United States, 1973-88. Advance Data from Vital and Health Statistics of the National Center for Health Statistics 1990; number 182.
7. Hawley HB. Gonorrhea. Finding and treating a moving target. Postgrad Med 1993; 94:105-111.
8. Centers for Disease Control and Prevention. Evaluation of surveillance for Chlamydia trachomatis infections in the United States, 1987 to 1991. JAMA 1993; 270:1676-1677.
9. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach DA, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiological associations. Am J Med 1983; 74:14-22.
10. Lee FK, Coleman RM, Pereira L, Bailey PD, Tatsuno M, Nahmias AJ. Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol 1985; 22:641-644.
11. Lee F, Pereira L, Griffin C, Reid E, Nahmias A. A novel glycoprotein for detection of herpes simplex virus type 1 specific antibodies. J Virol Meth 1986; 14:111-118.
12. Nahmias A, Lee FK, Pereira L, Reid E, Wickliffe C. Monoclonal antibody immunoaffinity purified glycoproteins for the detection of herpes simplex virus type 1 and type 2 specific antibodies in serum. In: Roizman B, Lopez C, eds. Immunobiology of Herpes Viruses. New York: Raven Press, Inc., 1986:201-210.
13. Carey RF, Herman WA, Retta SM, Rinaldi JE, Herman BA, Athey TW. Effectiveness of latex condoms as a barrier to human immunodeficiency virus-sized particles under conditions of simulated use. Sex Transm Dis 1992; 19:230-234.
14. Rietmeijer CAM, Krebs JW, Feorino PM, Judson FN. Condoms as physical and chemical barriers against human immunodeficiency virus. JAMA 1988; 259:1851-1853.
15. Conant MA, Spicer DW, Smith CD. Herpes simplex virus transmission: condom studies. Sex Transm Dis 1984; 11:94-95.
16. Katznelson S, Drew WL, Mintz L. Efficacy of the condom as a barrier to the transmission of cytomegalovirus. J Infect Dis 1984; 150:135-157.
17. Kish LS, McMahon JT, Bergfeld WF, Pelachyk JM. An ancient method and a modern scourge: the condom as a barrier against herpes [letter]. J Am Acad Dermatol 1983;9:769-770.
18. Minuk GY, Bohme CE, Bowen TJ, et al. Efficacy of commercial condoms in the prevention of hepatitis B virus infection. Gastroenterol 1987; 93:710-714.
19. Barlow D. The condom and gonorrhea. Lancet 1977; 2:811-813.
20. Judson FN, Ehret JM, Bodin GF, Levin MJ, Rietmeijer CAM. In vitro evaluations of condoms with and without nonoxynol-9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sex Transm Dis 1989; 16:51-56.
21. Pemberton J, McCann JS, Mahony JDH, MacKenzie G, Dougan H, Hay I. Socio-medical characteristics of patients attending a VD clinic and the circumstances of infection. Br J Vener Dis 1972; 48:391-396.
22. McCormack WM, Lee YH, Zinner SH. Sexual experience and urethral colonization with genital mycoplasms: a study in normal men. Ann Intern Med 1973; 78:696-698.
23. Hooper RR, Reynolds GH, Jones OG, et al. Cohort study of venereal disease. I: The risk of gonorrhea transmission from infected women to men. Am J Epidemiol 1978; 108:136-144.
24. Kelaghan J, Rubin GL, Ory HW, Layde PM. Barrier-method contraceptives and pelvic inflammatory disease. JAMA 1982; 248:184-187.
25. Oriel JD, Johnson AL, Barlow D, Thomas BJ, Nayyar K, Reeve P. Infection of the uterine cervix with Chlamydia trachomatis. J Infect Dis 1978; 137:443-451.
26. De Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N Engl J Med 1994; 331:341-346.
27. Hart G. Factors influencing venereal infection in a war environment. Br J Vener Dis 1974; 50:68-72.
28. Gotzsche PC, Hording M. Condoms to prevent HIV transmission do not imply truly safe sex. Scand J Infect Dis 1988; 20:233-234.
29. Grady WR, Tanfer K. Condom breakage and slippage among men in the United States. Fam Plann Perspect 1994; 26:107-112.
30. Jennings R, Clegg A. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in vitro. J Antimicrob Chemother 1993; 32:71-82.
31. Bourinbaiar AS, Lee-Huang S. Comparative in vitro study-of contraceptive agents with anti-HIV activity: gramicidin, nonoxynol-9, and gossypol. Contraception 1994; 49:131-137.
32. Hicks DR, Martin LS, Getchell JP, et al. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro [letter]. Lancet 1985; 2:1422-1423.
33. Bolch OH, Warren JC. In vitro effects of Emko on Neisseria gonorrhoeae and Trichomonas vaginalis. Am J Obstet Gynecol 1973; 115:1145-1148.
34. Cowan ME, Cree GE. A note in the susceptibility of N. Gonorrhoeae to contraceptive agent Nonyl-P. Br J Vener Dis 1973; 49:65-66.
35. Singh B, Cutler JC, Utidjian HM. Studies on the development of a vaginal preparation providing both prophylaxis against venereal disease and other genital infections and contraception. II. Effect in vitro of contraceptive and non-contraceptive preparations on Treponema pallidum and Neisseria gonorrhoeae. Br J Vener Dis 1972; 48:57-64.
36. Kelly JP, Reynolds RB, Stagno S, Louv WC, Alexander WJ. In vitro activity of the spermicide nonoxynol-9 against Chlamydia trachomatis. Antimicrob Agents Chemother 1985; 27:760-762.
37. Benes S, McCormack WM. Inhibition of growth of Chlamydia trachomatis by nonoxynol-9 in vitro. Antimicrob Agents Chemother 1985; 27:724-726.
38. Ehret JM, Judson FN. Activity of nonoxynol-9 against Chlamydia trachomatis. Sex Transm Dis 1988; 15:156-157.
39. Kappus EW, Quinn TC. The spermicide nonoxynol-9 does not inhibit Chlamydia trachomatis in vitro. Sex Transm Dis 1986; 13:134-137.
40. Roddy RE, Cordero M, Cordero C, Fortney JA. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 1993; 4:165-170.
41. Weir SS, Roddy RE, Zekeng L, Feldblum PJ. Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers. Genitourin Med 1995; 71:78-81.
42. Jick H, Hannan MT, Stergachis A, Heidrich F, Perera DR, Rothman KJ. Vaginal spermicides and gonorrhea. JAMA 1982; 248.169-1621.
43. Louv WC, Austin H, Alexander WJ, Stagno S, Cheeks J. A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infections. J Infect Dis 1988; 158:518-523.
44. Rosenberg MJ, Rojanapithayakorn W, Feldblum PJ, Higgins JE. Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis. A comparative clinical tnal. JAMA 1987; 257:2308-2312.
45. Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 1990; 163:510-514.
46. Niruthisard S, Roddy RE, Chutivongse S. Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydia cervical infections. Lancet 1992; 339:1371-1375.
47. Weir SS, Feldblum PJ, Zekeng L, Roddy RE. The use of nonoxynol-9 for protection against cervical gonorrhea. Am J Public Health 1994; 84:890-891.
48. Althaus F. Use or spermicide containing nonoxynol-9 provides substantial protection against gonorrheal infection. Fam Plann Perspect 1994; 26:234-235.
49. Carew B, Macaluso M, Austin H. Validity of reported use of barrier methods of contraception [Abstract]. Presented at the American Public Health Association, November 17-21, 1996, New York, NY.
50. Lawson L, Macaluso M, Carew B, Kelaghan J. Determinants of participation and retention in a prospective study of barrier contraception and STD prevention [Abstract]. Society for Epidemiologic Research, June 12-15, 1996, Boston, MA. Am J Epidemiol 1996; 143:S30.